Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
Aytu BioPharma (AYTU) has signed a definitive merger agreement to be acquired by Rosemont Pharmaceuticals. The acquisition will be executed through an all-cash tender offer at a price of $2.70 per share, conducted via a wholly-owned subsidiary of Rosemont. The deal aims to acquire all outstanding shares of Aytu common stock. This transaction follows recent financial disclosures from Aytu regarding its operating expense plans and margin targets for the upcoming fiscal periods.

Topics: acquisition merger agreement tender offer